Department of Anesthesiology and ICU, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Clinical Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Pain Pract. 2020 Jun;20(5):550-563. doi: 10.1111/papr.12874. Epub 2020 Feb 26.
The aim of this systematic review and meta-analysis was to appraise clinical evidence of the impact of peritonsillar infiltration of tramadol, on postoperative pain control and the occurrence of adverse effects in children undergoing tonsillectomy.
A database search was conducted to identify randomized controlled trials (RCTs) pertinent to peritonsillar infiltration of tramadol compared to no treatment (placebo) or other analgesic regimens. The outcomes of interest were postoperative pain intensity, time to first analgesic demand, rescue analgesic consumption up to 24 hours after intervention, and the occurrence of adverse events.
Twelve RCTs enrolling 972 pediatric patients were selected for qualitative analysis, among which eight were suitable for meta-analysis. Tramadol infiltration induced a significant reduction of pain intensity up to 24 hours post-tonsillectomy (mean difference [MD], -2.31; 95% confidence interval [CI], -3.49 to -1.12; P < 0.001; I = 97%) and time to first analgesic (MD 180.54; 95% CI, 56.91 to 304.18; P = 0.004; I = 99%), with no profound impact on postoperative nausea and vomiting (risk ratio [RR] 0.98; 95% CI, 0.73 to 1.32; P = 0.90; I = 0%) compared to the placebo group. The analgesic efficacy of tramadol infiltration was equivalent to the local or systematic use of ketamine or infiltration with local anesthetics. This effect was further enhanced when tramadol infiltration served as an adjunct to other analgesic interventions. No serious adverse events were reported.
In children undergoing tonsillectomy, peritonsillar infiltration of tramadol is associated with a postoperative analgesic benefit when compared to placebo, with negligible adverse events. Yet, no definite conclusion can be drawn due to the low quality, considerable heterogeneity, and paucity of the available data.
本系统评价和荟萃分析旨在评估扁桃体周围浸润曲马多对行扁桃体切除术儿童术后疼痛控制和不良反应发生的临床证据。
进行数据库检索以确定与扁桃体周围浸润曲马多相比无治疗(安慰剂)或其他镇痛方案的随机对照试验(RCT)。感兴趣的结局包括术后疼痛强度、首次镇痛需求时间、干预后 24 小时内补救性镇痛消耗以及不良事件的发生。
选择了 12 项纳入 972 名儿科患者的 RCT 进行定性分析,其中 8 项适合荟萃分析。曲马多浸润可显著降低扁桃体切除术后 24 小时内的疼痛强度(平均差异 [MD],-2.31;95%置信区间 [CI],-3.49 至-1.12;P<0.001;I²=97%)和首次镇痛时间(MD 180.54;95% CI,56.91 至 304.18;P=0.004;I²=99%),与安慰剂组相比,对术后恶心和呕吐没有显著影响(风险比 [RR] 0.98;95% CI,0.73 至 1.32;P=0.90;I²=0%)。与局部或全身使用氯胺酮或局部麻醉剂浸润相比,曲马多浸润的镇痛效果相当。当曲马多浸润作为其他镇痛干预的辅助手段时,这种效果进一步增强。未报告严重不良事件。
在接受扁桃体切除术的儿童中,与安慰剂相比,扁桃体周围浸润曲马多可带来术后镇痛益处,且不良反应发生率低。然而,由于低质量、高度异质性和现有数据的缺乏,尚不能得出明确结论。